teflubenzuron: effective against development of house fly larvae (Musca domestica) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
teflubenzuron : A N-acylurea that is N-carbamoyl-2,6-difluorobenzamide substituted by a 3,5-dichloro-2,4-difluorophenyl group at the terminal nitrogen atom. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 91734 |
| CHEMBL ID | 1328219 |
| CHEBI ID | 39387 |
| SCHEMBL ID | 26635 |
| MeSH ID | M0149226 |
| Synonym |
|---|
| LS-14260 |
| nsc367306 |
| mls000756919 , |
| 83121-18-0 |
| nsc-367306 |
| ac 291898 |
| calicide |
| n-(((3,5-dichloro-2,4-diflurophenyl)amino)carbonyl)-2,6-difluorobenzamide |
| mk 139 |
| hoe 522 |
| diaract |
| cme 134 |
| nomolt |
| teflubenzuron [bsi:iso] |
| dart |
| benzamide, n-(((3,5-dichloro-2,4-difluorophenyl)amino)carbonyl)-2,6-difluoro- |
| oms 3009 |
| tefluron |
| n-[(3,5-dichloro-2,4-difluorophenyl)carbamoyl]-2,6-difluorobenzamide |
| 1-(3,5-dichloro-2,4-difluorophenyl)-3-(2,6-difluorobenzoyl)urea |
| CHEBI:39387 , |
| n-{[(3,5-dichloro-2,4-difluorophenyl)amino]carbonyl}-2,6-difluorobenzamide |
| smr000528992 |
| teflubenzuron |
| 99039-56-2 |
| n-[(3,5-dichloro-2,4-difluoro-phenyl)carbamoyl]-2,6-difluoro-benzamide |
| A840507 |
| NCGC00246803-01 |
| C18437 |
| tox21_301448 |
| NCGC00255875-01 |
| dtxcid4022440 |
| dtxsid6042440 , |
| cas-83121-18-0 |
| HMS2886B17 |
| fs9p57vl74 , |
| ektobann |
| nsc 367306 |
| unii-fs9p57vl74 |
| FT-0641896 |
| AKOS015915472 |
| n-(((3,5-dichloro-2,4-difluorophenyl)amino)carbonyl)-2,6-difluorobenzamide |
| CHEMBL1328219 |
| SCHEMBL26635 |
| n-(2,4-difluoro-3,5-dichlorophenyl)-n'-(2,6-difluorobenzoyl)-urea |
| teflubenzuron [iso] |
| cme-134 |
| teflubenzuron [mi] |
| AC-23993 |
| teflubenzuron, pestanal(r), analytical standard |
| n-(3,5-dichloro-2,4-difluorophenylcarbamoyl)-2,6-difluorobenzamide |
| Q22808948 |
| teflubenzuron 100 microg/ml in methanol |
| CS-0014148 |
| HY-B2055 |
| teflubenzuron 1000 microg/ml in acetonitrile |
Teflubenzuron is a drug with potential to be used in Brazilian aquaculture. It attends to important requirements, such as low toxicity and high efficacy in controlling Trichodina spp.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Teflubenzuron is an in-feed pharmaceutical applied to control lice outbreaks; the standard medication is 10 mg per kg fish per day for seven days." | ( Exposure to teflubenzuron negatively impacts exploratory behavior, learning and activity of juvenile European lobster (Homarus gammarus). Agnalt, AL; Bjelland, RM; Browman, HI; Cresci, A; Durif, CMF; Samuelsen, OB; Skiftesvik, AB, 2018) | 1.58 |
| "Teflubenzuron is a drug with potential to be used in Brazilian aquaculture; it attends to important requirements, such as low toxicity and high efficacy in controlling Trichodina spp." | ( Teflubenzuron as a tool for control of trichodinids in freshwater fish: Acute toxicity and in vivo efficacy. Barbuio, R; Carraschi, SP; da Cruz, C; de Pádua, SB; Ikefuti, CV; Onaka, EM; Ranzani-Paiva, MJ, 2015) | 2.58 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Teflubenzuron did cause thrips mortality during the 24-h bioassay; it was more active against H haemorrhoidalis than F occidentalis." | ( Influence of a short exposure to teflubenzuron residues on the predation of thrips by Iphiseius degenerans (Acari: Phytoseiidae) and Orius laevigatus (Hemiptera: Anthocoridae). Blaney, WM; Scott Brown, AS; Simmonds, MS, 2003) | 1.32 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Therefore, the insecticide can be classified as being highly toxic to Daphnia magna, which means the agricultural and aquacultural uses of TFB pose a high risk of environmental toxicity to non-target organisms." | ( Acute toxicity and environmental risk of teflubenzuron to Daphnia magna, Poecilia reticulata and Lemna minor in the absence and presence of sediment. Carraschi, SP; Cruz, C; Machado-Neto, JG; Medeiros, LS; Souza, JP; Souza-Júnior, SC; Winkaler, EU, 2013) | 0.66 |
| " acute toxicity test for assessing the adverse effects of chemicals on aquatic invertebrates stipulates the use of neonates that are ≤24 h old (hours post release [hpr]) at the start of the exposure." | ( Age and Synchronization of Daphnia magna Affect Sensitivity to Teflubenzuron in Acute Standardized Toxicity Tests. Rundberget, JT; Schmid, S; Song, Y; Tollefsen, KE, 2023) | 1.15 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The sediment significantly reduced toxicity and bioavailability of TFB in water column." | ( Acute toxicity and environmental risk of teflubenzuron to Daphnia magna, Poecilia reticulata and Lemna minor in the absence and presence of sediment. Carraschi, SP; Cruz, C; Machado-Neto, JG; Medeiros, LS; Souza, JP; Souza-Júnior, SC; Winkaler, EU, 2013) | 0.66 |
The teflubenzuron was administered in the feed, at a dosage of 10 mg kg(-1) biomass d(-1), over a treatment period of 7 d. About 1.2 million first-year-class fish were included in the trial, of which approximately 561,000 received emamectin benzoate.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The metabolic fate of the insecticide teflubenzuron, orally dosed to the male Wistar rat, was investigated." | ( Metabolism of the insecticide teflubenzuron in rats. Cnubben, NH; De Kraker, JW; Koerts, J; Rietjens, IM; Soffers, AE, 1997) | 0.85 |
| "2 million first-year-class fish were included in the trial, of which approximately 561,000 received emamectin benzoate at a dosage of 50 microg kg(-1) body wt d(-1), while approximately 610,000 received teflubenzuron at a dosage of 10 mg kg(-1) body wt d(-1)." | ( Field trials in Norway with SLICE (0.2% emamectin benzoate) for the oral treatment of sea lice infestation in farmed Atlantic salmon Salmo salar. Colquhoun, DJ; Nordmo, R; Ramstad, A; Simmons, R; Sutherland, IH, 2002) | 0.5 |
| Role | Description |
|---|---|
| xenobiotic | A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. |
| environmental contaminant | Any minor or unwanted substance introduced into the environment that can have undesired effects. |
| insecticide | Strictly, a substance intended to kill members of the class Insecta. In common usage, any substance used for preventing, destroying, repelling or controlling insects. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dichlorobenzene | Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions. |
| N-acylurea | A member of the class of ureas that has the general formula R-CO-NH-CO-NH2 or R-CO-NH-CO-NH-CO-R', formally derived by the acylation of one or both of the nitrogens of a urea moiety. |
| difluorobenzene | Any member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying two fluorine atoms. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 0.2310 | 0.0041 | 10.8903 | 31.5287 | AID504467 |
| TDP1 protein | Homo sapiens (human) | Potency | 29.0929 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 47.3617 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| Smad3 | Homo sapiens (human) | Potency | 25.1189 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 21.1557 | 0.0010 | 22.6508 | 76.6163 | AID1224838 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 15.3758 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 35.8609 | 0.0002 | 29.3054 | 16,493.5996 | AID743069; AID743075 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 29.8832 | 0.0023 | 19.5956 | 74.0614 | AID651631 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID1091642 | Larvicidal activity against fourth-instar larval stage of Mythimna separata (Oriental armyworm) in compound-pretreated corn leaves assessed as mortality at 25 +/-1 degC after 4 days | 2008 | Journal of agricultural and food chemistry, Dec-10, Volume: 56, Issue:23 | Design, synthesis, bioactivity, and structure-activity relationship (SAR) studies of novel benzoylphenylureas containing oxime ether group. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (7.02) | 18.7374 |
| 1990's | 5 (8.77) | 18.2507 |
| 2000's | 15 (26.32) | 29.6817 |
| 2010's | 27 (47.37) | 24.3611 |
| 2020's | 6 (10.53) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (39.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (3.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 58 (96.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||